Informed Switching Strongly Decreases the Prevalence of Antibiotic Resistance in Hospital Wards by Kouyos, Roger D. et al.
Informed Switching Strongly Decreases the Prevalence
of Antibiotic Resistance in Hospital Wards
Roger D. Kouyos*, Pia Abel zur Wiesch, Sebastian Bonhoeffer
Institute of Integrative Biology, ETH Zurich, Zurich, Switzerland
Abstract
Antibiotic resistant nosocomial infections are an important cause of mortality and morbidity in hospitals. Antibiotic cycling
has been proposed to contain this spread by a coordinated use of different antibiotics. Theoretical work, however, suggests
that often the random deployment of drugs (‘‘mixing’’) might be the better strategy. We use an epidemiological model for a
single hospital ward in order to assess the performance of cycling strategies which take into account the frequency of
antibiotic resistance in the hospital ward. We assume that information on resistance frequencies stems from microbiological
tests, which are performed in order to optimize individual therapy. Thus the strategy proposed here represents an
optimization at population-level, which comes as a free byproduct of optimizing treatment at the individual level. We find
that in most cases such an informed switching strategy outperforms both periodic cycling and mixing, despite the fact that
information on the frequency of resistance is derived only from a small sub-population of patients. Furthermore we show
that the success of this strategy is essentially a stochastic phenomenon taking advantage of the small population sizes in
hospital wards. We find that the performance of an informed switching strategy can be improved substantially if
information on resistance tests is integrated over a period of one to two weeks. Finally we argue that our findings are robust
against a (moderate) preexistence of doubly resistant strains and against transmission via environmental reservoirs. Overall,
our results suggest that switching between different antibiotics might be a valuable strategy in small patient populations, if
the switching strategies take the frequencies of resistance alleles into account.
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Introduction
The increasing prevalence of antibiotic resistance in nosocomial
infections is a serious threat for clinical care and an important
cause for mortality and morbidlity as well as a substantial driver of
health care costs [1]. Several strategies to coordinate the use of
different drugs and thereby limiting the spread of antibiotic
resistance have been proposed. The most prominent such
strategies are Cycling (sequential use of different drugs), and
Mixing (simultaneous use of different drugs in different patients).
The rationale behind cycling is that strains resistant to the
formerly used drug may decrease in frequency or even disappear
in the off-period. Mixing, on the other hand, creates a strong
environmental heterogeneity that makes it difficult for the
pathogen to adapt. Concerning these two strategies, the clinical
literature is inconclusive [2,3], while the consensus in most of the
theoretical literature is that mixing almost always outperforms
cycling [4,5,6] (see however also the discussion in [7,8,9]). The
intuitive explanation for this pattern is that mixing leads to more
heterogeneity and hence hinders the adaptation of the bacterial
population against the antibiotic agents [4]. Thus it seems that
periodic switching of treatment regimes does not help to alleviate
the burden of antibiotic resistance in hospitals. On the other hand,
treatment decisions that take institution-antibiograms into account
[10] may lead to a cycling-like pattern in which antibiotics are
withdrawn when resistance rises and re-instituted when resistance
becomes more rare. It is often recommended that resistance
surveillance should be used as a guideline for empirical therapy
(i.e. therapy that is initiated before microbiological results are
available) [11]. However, it is difficult to disentangle the effects of
this particular strategy from other simultaneously used approaches
such as restriction of antibiotic usage [12].
Here, we use an epidemiological model for a hospital ward to
show that contrary to the current views switching between
different regimes of empirical therapy (i.e. treatment before the
causative pathogen and its resistance profile are known) can
reduce antibiotic resistance. The switching regime proposed here
differs from the traditional ones in [5] and [4] by taking the
frequencies of the resistant strain in the hospital into account.
Thus in contrast with ‘‘blind’’ periodic switching strategies, we
analyze informed switching strategies (ISS) similar to the ones that
arise by antibiogram-guided therapy and show that such strategies
can serve as valuable strategy to curb resistance.
Results
In this study we use an epidemiological model (see Figure 1 and
Tables 1–2) in order to consider the impact of several different
informed switching strategies (ISS), which coordinate the use of
two broad-spectrum antibiotics A and B on the level of a single
hospital ward (see Table 3 for a mathematical characterization of
the considered treatment strategies). The common element of
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suspected to have gone extinct only this ‘‘resistance-free’’ drug is
deployed. In this way, these strategies exploit the high frequency of
stochastic extinctions of resistant strains caused by the small
population sizes in hospitals. The crucial question for the practical
value of an ISS is whether such a strategy can substantially reduce
the burden of antibiotic resistance even if it is based on the
imperfect information, which can be obtained realistically. Here
we model the following realistic scenario of how such information
may be obtained: Commonly, symptomatically infected patients
are first treated empirically with a broad spectrum antibiotic, then
a resistance profile (microbiological tests) is determined (this
usually requires 1–2 days), which guides further therapy (optimally
with a narrow spectrum antibiotic). In our model we assume that
the ISS are based on the information obtained through these
microbiological tests, which are made to guide non-empirical
therapy of individual patients. Therefore, the model makes the
realistic assumptions that i) the information on the resistance status
of a symptomatically infected patient is only available after a delay
of 2 days on average and ii) that upon the availability of these test-
results, the patient is immediately put on a narrow-spectrum
therapy regimen against which the pathogen is susceptible. We
consider two main classes of ISS: those, which are based on a
snapshot of resistance frequencies (i.e. on the frequency of
resistance mutations among the infected patients that are currently
in the ward and of which microbiological results have been
obtained) or those, which integrate information of resistance over a
certain time window. Whereas the first class of strategies is simpler
to understand from a population biological point of view, we will
argue that strategies of the second class are recommendable for
clinical practice. We use two measures to assess the success of the
ISS (see method section): the prevalence of resistance mutations in
the ward and the number of inappropriately treated patients. In
fact, it has been shown that inappropriate initial (empirical)
treatment increases mortality since severely infected patients might
die before treatment can be adjusted [13,14]. For both measures
the success of an alternative strategy is measured relative to
mixing: if mM and mA denote the value of the measure for mixing
and the alternative therapy, respectively, then the success of the
alternative therapy is quantified by Dm=(m A2mM)/mM. Thus,
the more negative Dm, the better the strategy.
In order to study the population biological basis of the ISS, we
start by considering the simpler snapshot-based ISS: The negative-
frequency-dependent informed switching, ISS-, and the mixing-
like informed switching, ISSM. Both strategies deploy only one
drug if, among the infected patients in the ward whose resistance
status is known, there are both no reports of strains resistant
against this drug and at least one report of strains resistant against
the other drug (see Table 1). If no resistance mutation is present
both drugs are used at equal frequencies. The two strategies differ
with respect to their deployment of antibiotics when both
resistance mutations are present. In this case, ISS- deploys both
antibiotics inversely proportional to the momentary frequency of
the corresponding resistance mutations, whereas ISSM deploys
both antibiotics at equal frequencies. We find that informed
switching clearly outperforms both mixing and periodic cycling
(Figure 2). By contrast the difference between the two strategies
ISS- and ISSM is marginal (Figure 2). Thus the central aspect of
the strategies is the coordinated deployment of antibiotics in those
phases when one resistance mutation is extinct in the hospital. This
fact indicates that the success of ISS is essentially a stochastic
phenomenon, as extinctions are chance effects facilitated by small
hospital sizes. In accordance with this interpretation and with
earlier work[8,9], we find that, in the deterministic version of our
model, the ISS- strategy leads to no substantial improvement over
mixing (results not shown, but see section: effect of population size).
Considering only the current symptomatically infected patients
with a microbiological test leads to an imprecise estimate of the
resistance frequencies in the ward, as these patients represent only
a small fraction of all carriers. However, as the detection of one
infection with a resistant strain is indicative of other such infections
(which often persist after the detected case has been cleared) the
imprecision can, in part, be compensated by integrating the
information over several time points. The strategies ISSK (with
K=4,7,14,30,60,90) integrate information over several time-
points in the following way: A resistant strain is considered extinct
if no symptomatically infected patient with a microbiological test
that detected this strain has been in the hospital for the last K days
(see Table 3). Thus ISSK integrates the infection status (of patients
with a test) over the last K days. Again, if only one of resistance
mutations is considered extinct according to the above criterion,
then only the corresponding drug is used. If both or no resistance
mutation is considered extinct both drugs are used at equal
Figure 1. Flow chart of the model.
doi:10.1371/journal.pcbi.1001094.g001
Author Summary
Infections with bacterial pathogens that are resistant
against antibiotics are an important cause of mortality
and morbidity in hospitals. One possibility to minimize this
burden of antibiotic resistance is to coordinate the use of
several drugs at the level of a single hospital ward. Here,
we use a computational model of a hospital ward in order
to assess the performance of several such strategies that
take into account the frequency of antibiotic resistance in
the hospital ward. We assume that information on
resistance frequencies stems from microbiological tests,
which are performed routinely in order to optimize
individual therapy. Thus the strategy proposed here
represents an optimization at population-level, which
comes as a free byproduct of optimizing treatment at
the individual level. We find that in most cases our
informed strategy can substantially reduce the prevalence
of antibiotic resistance. We show that the performance of
an informed strategy can be improved substantially if
information on resistance tests is integrated over a period
of one to two weeks. Overall, our results suggest that
switching between different antibiotics might be a
valuable strategy in small patient populations, if the
switching strategies take the frequencies of resistance
alleles into account.
Informed Switching Decreases Resistance
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the choice of the length of the integration time window. An
alternative way to integrate information on resistance prevalence
over several days without this drawback is the following (ISSLast): If
at a given time-point the drug resistance-mutations against A and
B have been last detected (among the patients with known
resistance status) tA and tB days ago, then use that drug for which
this time-span is larger. If tA and tB are equal (in particular if both
resistance mutations are simultaneously present at the given time
point) then both drugs are used at the same frequency. We find
that both ways of integrating the information on resistance
frequencies can indeed substantially improve the performance of
the ISS and that the overall best results can be achieved for ISSLast
and for the ISSK with K=7 or 14 (Figure 3). Accordingly we will
focus on these two optimal strategies ISS7 and ISSLast, when
assessing in the following the robustness of our results with respect
to several important aspects of the model.
Impact of different levels of preexistence of the resistant
strains
One of the major factors determining the success of the ISS is the
frequency of resistant strains among incoming patients. The ISS are
based on extinctions of the resistance mutations, which is
counteracted by the frequent reintroduction of these strains.
Accordingly,we find that the successof ISS decreaseswith increasing
influx of resistant strains (Figure 4). However, the advantage of ISS
remains substantial unless an unrealistically large fraction of
incoming patients carries the resistant strain of the pathogen.
Impact of different progression rates
The progression rate is important mainly because it affects the
fraction of symptomatically infected patients and therefore the
frequency at which the antibiotic is used. With increasing
progression rate onewould expectan increasing use of the antibiotic
and hence an increasing impact of the applied strategy. Indeed, we
Table 1. Default model parameters of the model.
Parameter Explanation Default Value
pS Proportion susceptible among incoming patients 80%
pc Proportion carriers (infected and colonized) among incoming patients 20% [21]
pi Proportion of symptomatically infecteds among incoming patients 5%
pAB Proportion AB-resistant carriers among incoming infecteds and colonized patients 0%
pA0 Proportion A-resistant carriers among incoming infecteds and colonized patients 5%
p0B Proportion B-resistant carriers among incoming infecteds and colonized patients 5%
p00 Proportion carriers of the completely susceptible strain among incoming infecteds
and colonized patients
1-pAB-p0B-pA0
tR Rate with which symptomatically infected patients receive a microbiological test
and are switched to a narrow spectrum antibiotic.
0.5 d
21 [22]
b transmission rate (for colonized and infecteds) 0.05 d
21 *
a Rate with which empty beds are filled up 2 d
21
c Rate of treatment cessation in uninfected or asymptomatically infected patients 1/5 d
21
T Observation period over which results are averaged 30*365 d
cA0 cost of resistance against A 10% [23]
c0B cost of resistance against B 10% ‘‘
cAB cost of resistance against A and B 20% ‘‘
rcl Average time until carrier is not infectious when appropriately treated 2 days [24]
rp Rate of progression from colonized to infected 1/7 d
21
pr Cycling period 90 d [3]
N Number of beds 20
l Discharge + Death rate for asymptomatic patients 1/7 d
21**
li Discharge + Death rate for symptomatically infected patients 1/21+1/7 d
21
fA0,f 0B Frequency of infected patients treated with drug A or B see Table 3
Extension with environmental transmission in the hospital
cE Colonization rate of environment 1/10***
lE Turn-over rate of environment 1/30 d
21[25]
bE Transmission rate from environment b* lE/cE ***
*‘‘Colonization pressure’’, i.e. the frequency of both asymptomatic and symptomatic carriers in a hospital ward has been shown to be a major risk factor for the
acquisition of a nosocomial pathogen [26]. It also has been shown for clostridium difficile, that environmental contamination occurred for both symptomatic and
asymptomatic infections [27]. Nevertheless, it is conceivable that e.g. in symptomatically infected patients with diarrhea infectivity is much higher than in asymptomatic
patients. However, since the connection between carriage and infection is established and data on potential differences in infectivity between symptomatic and
asymptomatic patients are scarce, we chose not to distinguish between these two classes.
**The average length of stay is 8 days in Switzerland (http://www.obsandaten.ch/indikatoren/5_4_1/2005/d/541.pdf, data from 2005) and 5 days in the US (http://www.
cdc.gov/mmwr/preview/mmwrhtml/mm5427a6.htm).
***cE is an arbitrary. However, in order to make the environment comparable with direct transmission, the transmission rate bE from the environment is adjusted
depending on the decay and colonization rates, such that the R0 remains constant.
doi:10.1371/journal.pcbi.1001094.t001
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progressing diseases (Figure 5). However, even for moderate and
low progression rates, the ISS still confer a substantial advantage in
terms of reducing inappropriately treated patients.
Preexistence of doubly resistant strains
The preexistence of doubly resistant strains among incoming
patients has been argued to render treatment strategies futile, i.e.
strategies perform equally bad when doubly resistant strains are
Table 2. Summary of the different types of events underlying the stochastic implementation of the model.
event class Description of event Characterization of event (Ei) Rate of event (Ri)
1 Admission of uninfected patients S00?S00z1 an fb pS
2 Admission of asymptomatically infected patients C00
x ?C00
x z1 an fb pC(1{pI)px
3 Admission of symptomatically infected patients Iy
x?Iy
xz1 an fb pCpIpxfy for y=A0 or y=0B
4 Discharge of uninfected patients Sy?Sy{1 lS y
5 Discharge of asymptomatically infected patients Cy
x?Cy
x{1 lC y
x
6 Discharge of symptomatically infected patients Iy
x?Iy
x{1 lI Iy
x
7 Colonization of uninfected patient Sy?Sy{1
Cy
x?Cy
xz1
0 if strain x is susceptible to treatment
y lxSy otherwise
8 Progression of untreated asymptomatically
infected patients
C00
x ?C00
x {1
Iy
x?Iy
xz1
rpfyC00
x for y=A0 or y=0B
9 Progression of treated asymptomatically
infected patients
Cy
x?Cy
x{1
I
  y y
x?I
  y y
xz1
rpCy
x for y=A0 or y=0B (  y y~0B for y~A0
and   y y~A0 for y~0B)
10 Microbiological test results become available and
patient is put on narrow spectrum treatment
Iy
x?Iy
x{1
IN
x ?IN
x z1
tRIy
x for y=A0ory=0B
11 Clearance of symptomatically infected patient Iy
x?Iy
x{1
Sy?Syz1
rclIy
x if strain x is susceptible to
treatment y 0 otherwise
12 Cessation of therapy in uninfected patients Sy?Sy{1
S00?S00z1
cS y for y=00
13 Cessation of therapy in asymptomatically
infected patients
Cy
x?Cy
x{1
C00
x ?C00
x z1
cCy
x for y=00
This table follows the description and notation of Gillespie’s Direct Algorithm in Box 6.3 of [28]. If not stated otherwise the subscripts x range over the four possible
strains 00, A0, 0B, and AB and the superscripts y over the treatment states 00, A0, 0B and N (thus an event class can contain several events). Furthermore
nfb~N{(
P
y
Syz
P
x,y
Cy
xz
P
x,y
Iy
x) denotes the number of free beds, and lx~b(1{cx)
P
y
(Iy
xzCy
x)zbE(1{cx)Ex the force of infection for strain x.
doi:10.1371/journal.pcbi.1001094.t002
Table 3. Characterization of deployment strategies.
Strategy Characterization
mixing fA0=12Mf 0B =12M
cycling Alternating between (fA0=0,f0B=1)and(fA0=1,f0B=0) with period 90 days
Negative frequency dependent ISS: ISS-- fA~
QA
QAzQB
, fB~
QB
QAzQB
Mixing-like ISS If QA=0a n dQB.0t h e nfA0=1 and f0B=0
If QB=0a n dQA.0t h e nf0B=1 and fA0=0
Otherwise fA0=M and f0B=M
ISSK If t-tA.Ka n dt-tB#K then fA0=1,f0B=0
If t-tB.Ka n dt-tA#K then f0B=1,fA0=0
Otherwise then fA0=M, f0B=12M
ISSLast If tA.tB then fA0=1,f0B=0
If tB.tA then f0B=1,fA0=0
If tB=t A then fA0=0.5, f0B=0.5
M is a pre-specified constant, characterizing the relative use of drugs A and B in mixing phases (if not stated otherwise M=0.5). QA (QB) refers to the frequency of the
strain resistant to A (B) among patients with a known resistance profile (i.e. patients in treatment class N). Thus, QA~IN
A0zIN
AB and QB~IN
0BzIN
AB. t is the current time
point and tA (tB) the latest time-point at which resistance mutations against A (B) have been detected. In terms of the model described in Table 2, the time tA (tB) is given
by the latest time-point at which an event of class 10 with y=A0 (y=0B) has occurred.
doi:10.1371/journal.pcbi.1001094.t003
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above. Specifically we find that the beneficial impact of the ISS
decreases substantially as the fraction of incoming patients with a
doublyresistant strainincreases(Figure6).Thefigure,however,also
shows that the ISS can still substantially reduce the prevalence of
drug resistance even if the frequency of the doubly resistant strain is
as high as 5% among colonized and infected patients.
Transmission via an environmental reservoir
As the success of the ISS is essentially a stochastic effect, one
would expect that it becomes weaker in the presence of an
environmental reservoir. This is because an environmental
reservoir exhibits a slower turnover of strains (see Table 1) and
hence reduces the extinction risk of resistant strains, i.e. the
reservoir can act as a ‘‘seedbank’’ for resistant strains. Indeed, we
find that the ISS perform slightly worse in the presence of such a
reservoir (Figure 7). However this decrease in the strategies’
efficiency is very weak and the improvement achieved by applying
ISS7 remains substantial even if transmission is uniquely mediated
by an environmental reservoir. This indicates that even if the
turnover rate of strains in the ward is reduced to that of the
reservoir (here: 1/(30 days)) stochastic effects are strong enough to
ensure the efficiency of the ISS.
Impact of population size
The way in which the benefit conferred by the ISS depends on
population size confirms the stochastic nature of this effect: As
expected the benefit essentially disappears for very large population
sizes when stochastic effects are expected to be small (Figure 8).
Regarding the fraction of inappropriately treated patients the
magnitude of the benefit decreases monotonically with increasing
population size. Regarding the prevalence of resistance, we observe
however a slight increase in the magnitude when increasing the
population from 20 to 50. Although it is not entirely clear what
causes this increase, it might be that for very small population sizes
the subpopulation of patients with microbiological tests gives a very
inaccurate picture of the resistance prevalence even if integrated
over time. An alternative explanation is that in very small
populations, extinction events impede resistance emergence, such
that resistance is infrequent regardless of the treatment regimen. In
Figure 2. Relative change in prevalence of resistance mutations and of inappropriately treated patients compared to mixing for
different snapshot-based alternative strategies. Points correspond to the mean over 10
4 simulations, error-bars correspond to the 95%
confidence interval of the mean, inferred through 1000 bootstrap samples. Color indicates the prevalence of the resistant strains (pA0+p0B) among
incoming infected and colonized patients (black: 2% green: 10% blue: 20%).
doi:10.1371/journal.pcbi.1001094.g002
Figure 3. Relative change in prevalence of resistance mutations and of inappropriately treated patients compared to mixing for
different ISS that integrate resistance frequencies over time. Points correspond to the mean over 10
4 simulations, error-bars correspond to
the 95% confidence interval of the mean, inferred through 1000 bootstrap samples. Color indicates the prevalence of the resistant strains (pA0+p0B)
among incoming infected and colonized patients (black: 2% green: 10% blue: 20%).
doi:10.1371/journal.pcbi.1001094.g003
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However, as soon as the population size exceeds 100 the magnitude
of the effect decreases strongly (with regard to both measures) and
becomes negligible at population sizes of 500 and beyond.
Asymmetrical scenarios
For simplicity, we assumed so far that both resistance genes are
symmetrical, i.e. that resistance-costs and prevalence among
incoming patients carrying the resistant strain are identical for
drug A and B. If this assumption is relaxed, the optimal mixing
strategy does not deploy the two drugs at equal frequencies but
gives preference to the drug whose resistance mutation is more
frequent among incoming patients and less costly. We make the
realistic assumption that these two properties coincide: i.e. the less
costly mutations are more frequent. We find that in such an
asymmetric scenario, the ISS still considerably outperform even
the optimal mixing strategy (Figure 9). Interestingly, this scenario
provides the only example (apart from a very narrow parameter
region in Figure 3) in which the ISS7 strategy can outperform the
ISSLast strategy. However, the difference is rather small and
depends sensitively on choosing the correct mixing strategy for
those phases in which the ISS7 deploys both drugs simultaneously
(see definition of ISS in Table 3).
Discussion
Previous theoretical studies suggest that from the point of view of
preventing the spread of resistance mutations, mixing strategies
perform at least as good as strategies that switch between different
antibiotics [4,5]. However, selecting treatment based on cumulative
ward antibiograms has been shown to increase adequate therapy
[15]. Here, we haveshown that such a strategy doesnot onlybenefit
the single patients receiving appropriate therapy, but may also be
used to counteract the spread of resistance. In the highly stochastic
setting of small hospital wards, mixing (random treatment) can be
substantially outperformed by informed switching strategies, which
take the frequency of antibiotic resistance mutations into account.
Factors that promote the success of such ISS include the absence of
multiply resistant strains and a low frequency of singly resistant
strains among the incoming patients. However, even if these
conditions are not fulfilled, ISS can still substantially alleviate the
burden of drug resistance. Moreover, we found that the magnitude
of the effect of ISS decreases with increasing fitness cost, remains
however substantial even for large fitness costs (results not shown).
Given that, especially in the long term, resistance carries very small
costs if any [16], the default fitness cost chosen here (s=0.1) can be
considered as an upper bound yielding thus a conservative
assessment of the effect of ISS.
In our view, the most promising version of an informed switching
strategy is ISSLast. Apart from the fact that this strategy
outperformed the other versions in almost every setting, it has the
advantage that its implementation would be relatively simple:
Essentially, it would only require that the dates at which resistant
Figure 4. Relative change of resistance prevalence(left column)
and inappropriately treated patients (right column) compared
to mixing for ISS7 (green points) and ISSLast (black points). The
figures show the change induced by ISS7 and ISSLast as a function of the
resistance prevalence among incoming carriers, pA0+p0B, (x-axes) and
for different fractions of carriers, pC, among incoming patients (rows).
Points correspond to the mean over 10
4 simulations, error-bars
correspond to the 95% confidence interval of the mean, inferred
through 1000 bootstrap samples.
doi:10.1371/journal.pcbi.1001094.g004
Figure 5. Relative change of resistance prevalence and inappropriately treated patients compared to mixing for ISS7 (green points)
and ISSLast (black points). The figures show the change induced by ISS7 and ISSLast as a function of the rate of progression, rP, (x-axes). The right
panel shows how treatment frequency increases as a function of the rP. Points correspond to the mean over 10
4 simulations, error-bars correspond to
the 95% confidence interval of the mean, inferred through 1000 bootstrap samples.
doi:10.1371/journal.pcbi.1001094.g005
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everynewpatientthat drug isused forwhichthe lastisolationdate is
most distant. The main case in which we found this strategy not to
be the best choice, was if among incoming patients resistance
mutations against one drug was much more common than
resistance mutations against the alternative drug. In this situation
ISSLast clearly outperformed mixing. However, it was slightly worse
than the following alternative strategy: Always using the antibiotic
less common among incoming patients, except if a resistance
mutation against this drug has been detected in the past seven days,
in which case only the alternative drug has to be deployed (formally
this corresponds to ISS7 with M=0, see Table 3). However the
additional improvement conferred by this strategy was modest and
does in our view not outweigh the larger simplicity and robustness
(independence of an integration time-window) of ISSLast.
The benefit conferred by the ISS is a result of the underlying
stochasticity of resistance prevalence in the hospital. This is
demonstrated by our finding that the magnitude of the effect
becomes negligibly small as soon as the population size is above
500–1000. This is consistent with the findings of [8,9] which found
in a deterministic model no (or no substantial) improvement is
conferred by an ‘‘adaptive’’ strategy similar to the ISS used here.
The fact that ISS are very effective for small population sizes but
have limited success at large population sizes, suggests that
switching strategies should be implemented at the ward level
rather than at the hospital level, especially in large hospitals.
The information underlying the switching strategies considered
here is a byproduct of microbiological resistance tests, which are
usually done in clinical practice in order to optimize individual
treatments. While the recent HICPAC guidelines, ‘‘Management of
Multidrug-Resistant Organisms in Healthcare Settings,’’ [11]
recommend at least annual updates, the strategies proposed here
are not based on discrete updates. Instead the information acquired
from microbiological tests would have to be integrated into the
decisions as it is generated in the course of optimizing individual
treatments. Also, in accordance with current recommendations
[17,18] we follow resistance in one single hospital ward, not in the
whole institution, such that the cumulative antibiogram of the
respective wards should be chosen for informed switching. As the
success of an informed switching strategy depends on the quality of
the information on the frequencies of resistancegenes, the success of
the strategy can be further improved by sampling also asymptom-
atically infected patients (results not shown). However, we think that
the strategies we have proposed in this study represent the most
Figure 6. Relative change of resistance prevalence and inappropriately treated patients compared to mixing for ISS7 (green points)
and ISSLast (black points). The figure shows the change conferred by ISS7 and ISSLast as a function of pAB, the prevalence of the doubly resistant
strain among incoming carriers (x-axes). Points correspond to the mean over 10
4 simulations, error-bars correspond to the 95% confidence interval of
the mean, inferred through 1000 bootstrap samples.
doi:10.1371/journal.pcbi.1001094.g006
Figure 7. Relative change of resistance prevalence and inappropriately treated patients compared to mixing for ISS7 (green points)
and ISSLast (black points). The figure shows the change conferred by ISS7 and ISSLast for different relative impacts of the environmental reservoir
(x-axis). The relative impact of the reservoir is measured as the relative fraction of the force of infection that is mediated via the reservoir. Points
correspond to the mean over 10
4 simulations, error-bars correspond to the 95% confidence interval of the mean, inferred through 1000 bootstrap
samples.
doi:10.1371/journal.pcbi.1001094.g007
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than compiling the available data from microbiological tests.
Furthermore, the inclusion of isolates from asymptomatic patients
is not recommended by the Clinical and Laboratory Standards
Institute [CLSI] [19]. Thus although the extent of information is
important for informed switching strategies, a realistic and often
available degree of knowledge seems to be sufficient for a successful
implementation of the strategy.
In summary, we have shown that coordinated informed
switching of the antibiotic deployed in a hospital ward can
outperform mixing as a strategy to limit the spread of antibiotic
resistance of nosocomial pathogens. This theoretical result is
especially interesting, since the impact of surveillance-guided
therapy is often difficult to assess [12].
Methods
We consider a compartmental epidemiological model that
describes a single hospital ward. We further consider two empirical
broad spectrum antibiotics, to which we refer as drug A and B.
Accordingly, we follow four genotypes: wild type (sensitive to both
drugs), resistant against A and sensitive to B, resistant against B
and sensitive to A, and resistant against both drugs. Patients are
classified as being susceptible (S), colonized (C; i.e. asymptomatic
carriers), or infected (I; i.e. symptomatic carriers). Furthermore,
the compartments are subdivided according to the treatment status
and (for I & C) according to the genotype of the carried strain. In
addition, we follow a pathogen reservoir outside the patients (E),
which describes environmental contamination but may also
describe the dynamics resulting from the transient colonization
of health care workers; although these are not modeled explicitly.
Finally, we assume that symptomatically infected patients undergo
a microbial test (with a rate tR) after which they are switched to an
appropriate narrow spectrum antibiotic for which we assume that
resistance is negligible. These test-results provide the information
on resistance frequencies upon which the ISS are based.
Figure 1 summarizes the population dynamics of the model for a
single strainand Table1 liststheparametersand theirdefault values
(which are used if not declared explicitly otherwise). We used
parameter values from clinical literature as far as they are available.
Figure 8. Relative change of resistance prevalence and inappropriately treated patients compared to mixing for ISS7 (green points)
and ISSLast (black points). The figure shows the change conferred by ISS7 and ISSLast as a function of N, the number of beds in the ward. In order to
keep the R0 constant across different population sizes the transmission rate is assumed to be inversely proportional to the number of beds (i.e. b,1/
N). Points correspond to the mean over 10
4/(N/20) simulations (the number of samples was chosen inversely proportional to the population size
because, with the Gillespie algorithm used, simulation time increases proportionally with population size whereas the level of stochastic variation
decreases with population size), error-bars correspond to the 95% confidence interval of the mean, inferred through 1000 bootstrap samples.
doi:10.1371/journal.pcbi.1001094.g008
Figure 9. Relative change of resistance prevalence and inappropriately treated patients compared to mixing for ISS7 (green points)
and ISSLast (black points). The figure shows the change conferred by ISS7 and ISSLast for an asymmetric scenario in which pA0=0.1*2/3, p0B=0.1*1/
3, cA0=0.2 *1/3 and c0B=0.2*1/3 (i.e. the less costly mutant is more abundant). The x-axis corresponds to the mixing frequency M (see Table 3). Note
that the mixing and ISS7 depend on M, whereas ISSLast is independent of M. Points correspond to the mean over 10
4 simulations, error-bars
correspond to the 95% confidence interval of the mean, inferred through 1000 bootstrap samples.
doi:10.1371/journal.pcbi.1001094.g009
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soon as a bed is free, patients of all classes carrying pathogens of all
genotypes may be admitted at frequencies that are assumed to be
constant over the observed timeframe (see Table 1). The proportion
of incoming patients belonging to the three main compartments S,
C and I is determined by the parameters pS,p C and pI (see Table 1).
The proportion of patients carrying the genotypes wt, A, B, and AB
is given by the parameters pAB,p A0 and p0B. Upon admission
patients are not treated unless they are symptomatic carriers (i.e. we
focus on non-prophylactic treatment). Upon transition to the
‘‘infected’’ compartment all patients are treated with a broad-
spectrum antibiotic according to the current treatment strategy
(Mixing, Cycling or informed switching). After clearance of the
pathogen, treatment is ceased at a rate of 1/5 d
21.
Detailed model description
Here we consider a stochastic version of the model described above.
Specifically, the state of the patient-population in the ward is given by
the discrete variables Sy,Cy
x,Iy
x referring to the number of susceptible
(S) asymptomatically infected (C) and symptomatically infected (I)
patients with treatment status y and infection status x. The infection
status can be either ‘‘infected with the strain susceptible against both
drugs’’ (x=00), ‘‘infected with the strain susceptible against A but
resistant against B’’ (x=0B), ‘‘infected with the strain susceptible
against B but resistant against A’’ (x=A0), or ‘‘infected with the strain
resistant against both drugs’’ (x=AB). The treatment status can be
either ‘‘treatment with no drug’’ (y=00), ‘‘treatment with drug A’’
(y=A0), ‘‘treatment with drug B’’ (y=0B), or ‘‘treatment with a
narrow spectrum antibiotic’’ (y=N). We assume that the narrow-
spectrum antibiotic is only administered after microbiological tests and
that hence the infection status of patients in this treatment class is
known. The state of the environmental colonization is given by the
density Ex of the strain x in the environment.
The patient population is simulated stochastically according to
Gillespie’s Direct Algorithm[20]. The full characterization of this
model is given by Table 2, which lists the different events (and
rates) that constitute the model. The following points should be
noted concerning these events:
N Symptomatically infected patients are always subject to
monotherapy, thus I00
x ~0 for all x and accordingly the
dynamics of these variables is not considered.
N According to the model dynamics, asymptomatically infected
patients are never treated with narrow spectrum antibiotic
hence the variables CN
x are constantly 0 and therefore ignored
in the model.
N Upon admission or progression, symptomatically infected
patients are first treated with a broad-spectrum antibiotic
(empirical therapy) (see event classes 3,8, and 9 in Table 2).
Then these patients receive microbiological tests with a rate tR
and are switched to a narrow spectrum-treatment as soon as
these test results are available (event class 10).
N If an asymptomatically infected patient becomes symptomatic
despite treatment with a broad-spectrums antibiotic, then the
broad-spectrum drug used for that patient is switched (from A
to B and from B to A)(event class 9).
N The rates for several event-classes (classes 7 and 11) depend on
whether strain x is sensitive to treatment y. Strain 00 is
susceptible against all drugs. Strain A0 is susceptible against
drug B and against the narrow-spectrum antibiotics (N). Strain
0B is susceptible against drug A and against the narrow-
spectrum antibiotics (N). Strain AB is only susceptible against
narrow-spectrum antibiotics (N).
N The broad spectrum antibiotics are A and B are used at
frequencies fA0 and f0B. These frequencies are determined by
the treatment strategy deployed. A summary of treatment
strategies is given in Table 3.
As the dynamics of the environmental compartment is not
directly affected by the fluctuations of the patient population, the
variables Ex describing the environmental reservoir are updated
according to the ODE system
_ E Ex~cE
X
y
(Iy
xzCy
x){lEEx
The success of the treatment strategies (summarized in Table 3)
is measured by their impact on the prevalence of resistance
given by
P
y
(I
y
A0zC
y
A0zI
y
ABzC
y
AB)z
P
y
(I
y
0BzC
y
0BzI
y
ABzC
y
AB)
(note that double resistant strains are counted twice) and by their
impact on the number of inappropriately treated patients given by
(IA0
A0zIA0
AB)z(I0B
0BzI0B
AB). (Note that for this measure we take only
symptomatically infected patients into account, because it is in that
group thatinappropriatetreatmentwillhave themostsevereclinical
consequences).
Author Contributions
Conceived and designed the experiments: RDK PAzW SB. Performed the
experiments: RDK PAzW. Analyzed the data: RDK PAzW. Wrote the
paper: RDK PAzW SB.
References
1. Niederman MS (2001) Impact of antibiotic resistance on clinical outcomes and
the cost of care. Crit Care Med 29: N114–120.
2. Brown EM, Nathwani D (2005) Antibiotic cycling or rotation: a systematic
review of the evidence of efficacy. J Antimicrob Chemother 55: 6–9.
3. Masterton RG (2005) Antibiotic cycling: more than it might seem? J Antimicrob
Chemother 55: 1–5.
4. Bergstrom CT, Lo M, Lipsitch M (2004) Ecological theory suggests that
antimicrobial cycling will not reduce antimicrobial resistance in hospitals. Proc
Natl Acad Sci U S A 101: 13285–13290.
5. Bonhoeffer S, Lipsitch M, Levin BR (1997) Evaluating treatment protocols to
prevent antibiotic resistance. Proc Natl Acad Sci U S A 94: 12106–12111.
6. Reluga TC (2005) Simple models of antibiotic cycling. Math Med Biol 22:
187–208.
7. Beardmore RE, Pena-Miller R (2010) Antibiotic Cycling Versus Mixing: The
Difficulty of Using Mathematical Models to Definitively Quantify Their Relative
Merits. Math Biosci Eng 7: 923–933.
8. Beardmore RE, Pena-Miller R (2010) Rotating Antibiotics Selects Optimally
against Antibiotic Resistance, in Theory. Math Biosci Eng 7: 527–552.
9. Bonhoeffer S, zur Wiesch PA, Kouyos RD (2010) Rotating Antibiotics Does Not
Minimize Selection for Resistance. Math Biosci Eng 7: 919–922.
10. Evans RS, Pestotnik SL, Classen DC, Clemmer TP, Weaver LK, et al. (1998) A
computer-assisted management program for antibiotics and other antiinfective
agents. N Engl J Med 338: 232–238.
11. Siegel JD, Rhinehard E, Jackson M, Chiarello L, the Healthcare Infection
Control Practices Advisory Committeee (2006) Management of Multidrug-
Resistant Organisms in Healthcare Settings, 2006. CDC. Avilable: http://www.
cdc.gov/ncidod/dhqp/pdf/ar/mdroGuideline2006.pdf.
12. Masterton RG (2000) Surveillance studies: how can they help the management
of infection? J Antimicrob Chemother 46 (Suppl T2): 53–58.
13. Falagas ME, Kasiakou SK, Rafailidis PI, Zouglakis G, Morfou P (2006)
Comparison of mortality of patients with Acinetobacter baumannii bacteraemia
receiving appropriate and inappropriate empirical therapy. J Antimicrob
Chemother 57: 1251–1254.
14. Kollef M (2003) Appropriate empirical antibacterial therapy for nosocomial
infections: getting it right the first time. Drugs 63: 2157–2168.
15. Burgmann H, Stoiser B, Heinz G, Schenk P, Apfalter P, et al. (2009) Likelihood
of inadequate treatment: a novel approach to evaluating drug-resistance
patterns. Infect Control Hosp Epidemiol 30: 672–677.
16. Andersson DI (2006) The biological cost of mutational antibiotic resistance: any
practical conclusions? Curr Opin Microbiol 9: 461–465.
Informed Switching Decreases Resistance
PLoS Computational Biology | www.ploscompbiol.org 9 March 2011 | Volume 7 | Issue 3 | e100109417. Binkley S, Fishman NO, LaRosa LA, Marr AM, Nachamkin I, et al. (2006)
Comparison of unit-specific and hospital-wide antibiograms: potential implica-
tions for selection of empirical antimicrobial therapy. Infect Control Hosp
Epidemiol 27: 682–687.
18. Green DL (2005) Selection of an empiric antibiotic regimen for hospital-
acquired pneumonia using a unit and culture-type specific antibiogram.
J Intensive Care Med 20: 296–301.
19. Pakyz AL (2007) The utility of hospital antibiograms as tools for guiding empiric
therapy and tracking resistance. Insights from the Society of Infectious Diseases
Pharmacists. Pharmacotherapy 27: 1306–1312.
20. Gillespie DT (1976) General Method for Numerically Simulating Stochastic
Time Evolution of Coupled Chemical-Reactions. J Comput Phys 22: 403–434.
21. Wertheim HF, Melles DC, Vos MC, van Leeuwen W, van Belkum A, et al.
(2005) The role of nasal carriage in Staphylococcus aureus infections. Lancet
Infect Dis 5: 751–762.
22. Andrews JM (2001) BSAC standardized disc susceptibility testing method.
J Antimicrob Chemother 48 (Suppl 1): 43–57.
23. Trindade S, Sousa A, Xavier KB, Dionisio F, Ferreira MG, et al. (2009) Positive
epistasis drives the acquisition of multidrug resistance. PLoS Genet 5: e1000578.
24. Ottiger C, Schaer G, Huber AR (2007) Time-course of quantitative urinary
leukocytes and bacteria counts during antibiotic therapy in women with
symptoms of urinary tract infection. Clin Chim Acta 379: 36–41.
25. Neely AN, Maley MP (2000) Survival of enterococci and staphylococci on
hospital fabrics and plastic. J Clin Microbiol 38: 724–726.
26. Bonten MJM, Slaughter S, Ambergen AW, Hayden MK, van Voorhis J, et al.
(1998) The Role of ‘‘Colonization Pressure’’ in the Spread of Vancomycin-
Resistant Enterococci: An Important Infection Control Variable. Arch Intern
Med 158: 1127–1132.
27. McFarland LV, Mulligan ME, Kwok RYY, Stamm WE (1989) Nosocomial
Acquisition of Clostridium difficile Infection. New Engl J Med 320: 204–210.
28. Keeling MJ, Rohani P (2007) Modeling Infectious Diseases in Humans and
Animals: Princeton University Press.
Informed Switching Decreases Resistance
PLoS Computational Biology | www.ploscompbiol.org 10 March 2011 | Volume 7 | Issue 3 | e1001094